Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Adavosertib + Olaparib|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Adavosertib||MK-1775|AZD1775|AZ1775||WEE1 Inhibitor 4||Adavosertib (MK-1775) is a small molecule inhibitor of the tyrosine kinase WEE1 with potential antineoplastic sensitizing activity (PMID: 22084170).|
|Olaparib||Lynparza||AZD2281|KU-0059436||PARP Inhibitor (Pan) 19||Lynparza (olaparib) binds to and inhibits PARP, resulting in inhibition of DNA repair and lethality in homologous-recombination deficient cells, and may be a sensitizing agent for chemotherapy and radiotherapy (PMID: 25028150, PMID: 24225019). Lynparza (olaparib) is FDA approved for treatment of ERBB2 (HER2)-negative breast cancer with deleterious or suspected deleterious germline BRCA mutations, ovarian cancer with deleterious or suspected deleterious germline BRCA mutations and received 3 or more prior therapies, metastatic pancreatic adenocarcinoma with deleterious or suspected deleterious germline BRCA mutations as a maintenance therapy, metastatic castration-resistant prostate cancer with deleterious or suspected deleterious germline or somatic homologous recombination repair gene mutations who progressed following enzalutamide or abiraterone, as a maintenance therapy in recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer and in epithelial ovarian, fallopian tube or primary peritoneal cancer with deleterious or suspected deleterious germline or somatic BRCA mutation, and in combination with Avastin (bevacizumab) as maintenance therapy in HDR defective epithelial ovarian, fallopian tube or primary peritoneal cancer as defined by deleterious or suspected deleterious BRCA mutation, and/or genomic instability (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||Advanced Solid Tumor||not applicable||Adavosertib + Olaparib||Phase Ib/II||Actionable||In a Phase Ib trial, Adavosertib (MK-1775) and Lynparza (olaparib) combination therapy resulted in partial response in 17% (1/6) and stable disease in 67% (4/6) of patients with advanced solid tumors (J Clin Oncol 34, 2016 (suppl; abstr 5562)).||detail...|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT04197713||Phase I||Adavosertib + Olaparib||Testing the Sequential Combination of the Anti-cancer Drugs Olaparib Followed by Adavosertib (AZD1775) in Patients With Advanced Solid Tumors With Selected Mutations and PARP Resistance, STAR Study||Recruiting|
|NCT02576444||Phase II||Adavosertib + Olaparib Olaparib Olaparib + Vistusertib Capivasertib + Olaparib AZD6738 + Olaparib||OLAParib COmbinations (OLAPCO)||Active, not recruiting|
|NCT03579316||Phase II||Olaparib Adavosertib + Olaparib||Adavosertib With or Without Olaparib in Treating Participants With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer||Recruiting|
|NCT03330847||Phase II||Adavosertib + Olaparib Olaparib AZD6738 + Olaparib||To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy||Recruiting|